Christoph Niessen1, Eva Unterpaintner2, Holger Goessmann2, Hans J Schlitt3, Martina Mueller-Schilling4, Walter A Wohlgemuth2, Christian Stroszczynski2, Philipp Wiggermann2. 1. Department of Radiology, University Hospital Regensburg, Franz-Josef Strauss Allee 11, 93042 Regensburg, Germany. Electronic address: christoph.niessen@ukr.de. 2. Department of Radiology, University Hospital Regensburg, Franz-Josef Strauss Allee 11, 93042 Regensburg, Germany. 3. Department of Surgery, University Hospital Regensburg, Franz-Josef Strauss Allee 11, 93042 Regensburg, Germany. 4. Department of Internal Medicine I, University Hospital Regensburg, Franz-Josef Strauss Allee 11, 93042 Regensburg, Germany.
Abstract
PURPOSE: To compare outcomes of transarterial chemoembolization with degradable starch microspheres (DSMs) and conventional transarterial chemoembolization with doxorubicin and Ethiodol in patients with unresectable intermediate-stage hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A total of 69 patients underwent 169 chemoembolization procedures with Ethiodol (n = 35) or DSMs (n = 34) as the embolic agent. The same chemotherapeutic agent was used for all patients (50 mg doxorubicin). The primary endpoint was patient survival, and secondary endpoints were local tumor response and incidence of therapy-associated complications with conventional or DSM chemoembolization. Tumor response was evaluated by consensus reading by two radiologists in accordance with modified Response Evaluation Criteria In Solid Tumors. Mean survival was calculated according to Kaplan-Meier analysis, and differences in survival curves were assessed by univariate log-rank test. The statistical significance of quantitative variables was determined by parameter-free Wilcoxon-Mann-Whitney U test. RESULTS: The study groups were similar with regard to demographic data and disease stage. For the DSM chemoembolization group, the objective response rate (ie, complete or partial response) was 44.1%, and the rate of stable disease was 38.2%. The respective rates for the conventional chemoembolization group were 48.6% and 31.4%. Mean survival (P = .337) and complications did not significantly differ between groups (P = .907; P = 1.000). CONCLUSIONS: DSM chemoembolization represents an alternative method of HCC treatment with a safety profile similar to that of conventional transarterial chemoembolization. Regarding local tumor response and overall survival, results of DSM chemoembolization were similar to those of conventional chemoembolization.
PURPOSE: To compare outcomes of transarterial chemoembolization with degradable starch microspheres (DSMs) and conventional transarterial chemoembolization with doxorubicin and Ethiodol in patients with unresectable intermediate-stage hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A total of 69 patients underwent 169 chemoembolization procedures with Ethiodol (n = 35) or DSMs (n = 34) as the embolic agent. The same chemotherapeutic agent was used for all patients (50 mg doxorubicin). The primary endpoint was patient survival, and secondary endpoints were local tumor response and incidence of therapy-associated complications with conventional or DSM chemoembolization. Tumor response was evaluated by consensus reading by two radiologists in accordance with modified Response Evaluation Criteria In Solid Tumors. Mean survival was calculated according to Kaplan-Meier analysis, and differences in survival curves were assessed by univariate log-rank test. The statistical significance of quantitative variables was determined by parameter-free Wilcoxon-Mann-Whitney U test. RESULTS: The study groups were similar with regard to demographic data and disease stage. For the DSM chemoembolization group, the objective response rate (ie, complete or partial response) was 44.1%, and the rate of stable disease was 38.2%. The respective rates for the conventional chemoembolization group were 48.6% and 31.4%. Mean survival (P = .337) and complications did not significantly differ between groups (P = .907; P = 1.000). CONCLUSIONS: DSM chemoembolization represents an alternative method of HCC treatment with a safety profile similar to that of conventional transarterial chemoembolization. Regarding local tumor response and overall survival, results of DSM chemoembolization were similar to those of conventional chemoembolization.
Authors: Antonio Orlacchio; Fabrizio Chegai; Stefano Merolla; Simona Francioso; Costantino Del Giudice; Mario Angelico; Giuseppe Tisone; Giovanni Simonetti Journal: World J Hepatol Date: 2015-06-28
Authors: Thomas J Vogl; Christian Marko; Marcel C Langenbach; Nagy N N Naguib; Natalie Filmann; Renate Hammerstingl; Tatjana Gruber-Rouh Journal: Eur Radiol Date: 2020-09-22 Impact factor: 5.315
Authors: Antonio Orlacchio; Fabrizio Chegai; Simona Francioso; Stefano Merolla; Serena Monti; Mario Angelico; Giuseppe Tisone; Lorenzo Mannelli Journal: Curr Med Imaging Rev Date: 2018-08
Authors: Marie Vogeler; Isabelle Mohr; Jan Pfeiffenberger; Simon David Sprengel; Miriam Klauss; Boris Radeleff; Andreas Teufel; De-Hua Chang; Christoph Springfeld; Thomas Longerich; Uta Merle; Arianeb Mehrabi; Karl Heinz Weiss; Markus Mieth Journal: J Cancer Res Clin Oncol Date: 2022-01-25 Impact factor: 4.322